Heinrich Dreismann
Independent DirectorDr. Heinrich Dreismann, Ph.D., also known as Heiner, is Director of Nucleix Ltd. He is Chairman of Biofidelity Ltd. Dr. Dreismann has Ph.D. in Microbiology, Microbiology, Molecular Biology, Molecular Biology from Universität Münster in 2014. Dr. Dreismann has M.S. in Biology from Universität Münster. Dr. Heinrich Dreismann, serves as Director of GestVision, Inc. He is Director of Fortis Life Sciences LLC from 2025. Dr. Dreismann was Independent Director at Talis Biomedical Corporation from May 23, 2023 until August 01, 2024. Dr. Dreismann serves as a Director at Inflammatix, Inc. since July 2023. He was Non-Executive Chairman of Quantum Cyber N.V. (formerly known as Mainz Biomed N.V.) from December 14, 2022 and served as Non-Executive Director until April 22, 2026. He serves as Chairman of Biofidelity Ltd. He served as Strategy Advisory Board at Mainz Biomed B.V. since November 11, 2021 until December 14, 2022. He serves as Member of Advisory Panel at Cambridge Innovation Capital Limited. He serves as Chairman at MobilION Systems, Inc. Dr. Dreismann serves as an Independent Director at DNA Script SAS. Dr. Dreismann serves as Senior Independent Non-Executive Director at Congenica Ltd. since November 2019. Dr. Dreismann has been Chairman of the Executive Advisory Board of MyDx, Inc. since April 24, 2018. He serves as a Director of GestVision, Inc. He serves as Advisor and Consultant at Kurma Partners. Dr. Dreismann served as Chief Executive Officer of Vectrant Technologies Inc. from 2006 to 2009. Dr. Dreismann served as a Venture Partner at SV Health Investors, LLC since 2011. He joined SV Health Investors, LLC on October 5, 2011. He was part of the biotechnology team and focused on In Vitro Diagnostics, diagnostics, biotechnology, biopharmaceuticals, medical devices and instrumentation and healthcare services. He served as the Head of Diagnostics at MetaStat, Inc. since October 2013 and served as its Diagnostic Consultant from October 2013 to August 4, 2016. He served as an Interim Chief Executive Officer of GeneNews Limited from May 31, 2008 to July 12, 2013. He served as an Executive Advisor at Ignyta, Inc. since January 2012. He had a successful career at the Roche Group from 1985 to 2006. He served as the Chief Executive Officer and President of Roche Molecular Systems. He co-founded Integrated Diagnostics Inc. in 2005 and served as its Executive Chairman. Dr. Dreismann served as the President of Roche Molecular Systems Inc. since January 2001 and as its Chief Executive Officer from 2000 to 2006 and oversaw significant expansion of its product portfolio. He was Employed at Roche Diagnostics Corporation and served as its Head of Global Business Development, Head of Business Unit of PCR Europe since 1991, Head of Business unit Microbiology and Vice President of Manufacturing as well as R&D positions in microbiology and infectious diseases and in manufacturing and served as Business Unit Manager of PCR and Microbiology. He served as Head of Integration Office of Roche Diagnostics, where he managed the merger of Boehringer Mannheim at Roche Diagnostics. In his last role at RMS, he oversaw the doubling of the molecular in vitro diagnostics business and had overall responsibilities for business, corporate and R&D functions, as well as the respective staff. Dr. Dreismann served in a number of other leadership capacities at Roehm GmbH, dating back to 1983. He led the introduction of PCR-based tests in Europe as early as 1992 and witnessed firsthand the industry growth over the last two decades. He is a veteran of the molecular diagnostics industry and has a wealth of experience and contacts. Dr. Dreismann is a seasoned executive with experience in the health care industry and is regarded as a pioneer in the early adoption of the polymerase chain reaction (PCR) technique. He serves as the Chairman of the Board at Spinomix SA. Dr. Dreismann serves as the Chairman of Optimal Medicine Ltd. He served as the Chairman of TheraGenetics Ltd. and Smart Holograms Limited. He served as the Chairman of Business Advisory Board at Shrink Nanotechnologies, Inc. He serves on the boards of several innovative public and private diagnostic companies. He served as a Director of Ignyta, Inc. since October 31, 2013 until February 8, 2018. Dr. Dreismann has been a Director of Magellan Diagnostics, Inc. since August 2007, Celula, Inc. since 2009. Dr. Dreismann has been an Independent Director at Myriad Genetics, Inc. since June 2010. He served as a Director of Ixcela, Inc. until 2021. He serves as Chairman of the Board at Sense Biodetection Limited. Dr. Dreismann is Executive Investment Advisor at GrayBella Capital. Dr. Dreismann serves on several boards of biotech and diagnostic companies. He is Member of the New York Academy of Sciences & American Society of Microbiology. He joined F. Hoffmann La Roche AG in 1985 and held various national and international management positions, including head of the Business Area Microbiology. He serves as the Director MedCision, Inc. Stratos Genomics Inc. BioCision, LLC, BioHelix Corporation, Vectrant Technologies and AlliedPath. He serves as an Independent Director at AdvanDx, Inc. since March 27, 2013. He has been Director of Stemina Biomarker Discovery, Inc. since August 2017. He has been a Director of Singulex, Inc. since January 2007 and serves as its Lead Independent Director. He had been Member of Business Advisory Board at Telo Genomics Corp. (formerly known as 3D Signatures Inc.) since October 2016. He served as a Director of Adarza BioSystems, Inc. He served as a Lead Director of GeneNews Limited from May 31, 2008 to November 4, 2016 and its Independent Director from September 19, 2006 to November 4, 2016. He served as a Director of Shrink Nanotechnologies, Inc. from June 22, 2009 to November 1, 2011. He served as a Director of Integrated Diagnostics Inc. He served as a Director of Interpace Diagnostics Group, Inc. since August 13, 2014 until September 29, 2016. He served as a Director of Sirius Genomics Inc. since November 2008. He served as a Director at Med BioGene Inc. from May 29, 2008 to September 5, 2014 and Iconix Biosciences, Inc. since October 24, 2006. He serves on the boards of several public and private health care companies. He served as a Director of HistoRx, Inc. since October 2010 and Oxford BioDynamics Plc since October 2008. He served as a Director of Ngen, Inc. from October 31, 2006 to August 2009. He served as a Member of Business Advisory Board at Shrink Nanotechnologies, Inc. Dr. Dreismann has a Post-Doctoral Fellowship from the French Center for Nuclear Research in Saclay, near Paris, France.
Positions
- Company NameMyriad Genetics, Inc.Stock CodeMYGNPositionIndependent DirectorColleagues
- SSSamraat S. RahaPresident, CEO & Director
- SLS. Louise PhanstielIndependent Chair of the Board
- BRBenjamin R. WheelerCFO & Principal Accounting Officer
- MSMark S. VerrattiChief Operating Officer
- DMDale MuzzeyChief Scientific Officer
- PJPaul J. DiazConsultant
- CFColleen Foley ReitanIndependent Director
- MSMark S. DavisIndependent Director
